Document Detail


Effects of (-)-epicatechin on myocardial infarct size and left ventricular remodeling after permanent coronary occlusion.
MedLine Citation:
PMID:  20579545     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: We examined the effects of the flavanol (-)-epicatechin on short- and long-term infarct size and left ventricular (LV) structure and function after permanent coronary occlusion (PCO) and the potential involvement of the protective protein kinase B (AKT)/extracellular signal-related kinase (ERK) signaling pathways.
BACKGROUND: (-)-epicatechin reduces blood pressure in hypertensive patients and limits infarct size in animal models of myocardial ischemia-reperfusion injury. However, nothing is known about its effects on infarction after PCO.
METHODS: (-)-epicatechin (1 mg/kg daily) treatment was administered via oral gavage to 250 g male rats for 10 days before PCO and was continued afterward. The PCO controls received water. Sham animals underwent thoracotomy and treatment in the absence of PCO. Immunoblots assessed AKT/ERK involvement 2 h after PCO. The LV morphometric features and function were measured 48 h and 3 weeks after PCO.
RESULTS: In the 48-h group, treatment reduced infarct size by 52%. There were no differences in hemodynamics among the different groups (heart rate and aortic and LV pressures). Western blots revealed no differences in AKT or ERK phosphorylation levels. At 3 weeks, PCO control animals demonstrated significant increases in LV end-diastolic pressure, heart and body weight, and LV chamber diameter versus sham. The PCO plus (-)-epicatechin group values were comparable with those of the sham plus (-)-epicatechin group. Treatment resulted in a 33% decrease in myocardial infarction size. The LV pressure-volume curves demonstrated a right shift in control PCO animals, whereas the (-)-epicatechin curves were comparable with those of the sham group. The LV scar area strains were significantly improved with (-)-epicatechin.
CONCLUSIONS: These results demonstrate the unique capacity of (-)-epicatechin to confer cardioprotection in the setting of a severe form of myocardial ischemic injury. Protection is sustained over time and preserves LV structure and function. The cardioprotective mechanism(s) of (-)-epicatechin seem to be unrelated to AKT or ERK activation. (-)-epicatechin warrants further investigation as a cardioprotectant.
Authors:
Katrina Go Yamazaki; Pam R Taub; Maraliz Barraza-Hidalgo; Maria M Rivas; Alexander C Zambon; Guillermo Ceballos; Francisco J Villarreal
Related Documents :
1424005 - Effects of dynamic cardiomyoplasty on regional wall motion, ejection fraction, and geom...
9808605 - Electromechanical characterization of chronic myocardial infarction in the canine coron...
3704595 - Echocardiographic assessment of left ventricular function in left ventricular volume lo...
17174235 - Clinical features of isolated ventricular noncompaction in adults long-term clinical co...
11515695 - Myocardial uptake and release of substrates in type ii diabetics undergoing coronary su...
16942455 - A modified postural drainage position produces less cardiovascular stress than a head-d...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  55     ISSN:  1558-3597     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-06-28     Completed Date:  2010-07-20     Revised Date:  2014-09-21    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2869-76     Citation Subset:  AIM; IM    
Copyright Information:
Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Analysis of Variance
Animals
Catechin / pharmacology*
Coronary Circulation
Coronary Occlusion / drug therapy*,  mortality,  radiography
Disease Models, Animal
Hemodynamics / physiology*
Male
Myocardial Infarction / drug therapy*,  mortality,  pathology,  prevention & control*
Myocardial Reperfusion Injury / prevention & control
Probability
Random Allocation
Rats
Rats, Sprague-Dawley
Reference Values
Survival Rate
Treatment Outcome
Ventricular Remodeling / drug effects*,  physiology
Grant Support
ID/Acronym/Agency:
AT-004277/AT/NCCAM NIH HHS; HL-43617/HL/NHLBI NIH HHS; R01 HL043617/HL/NHLBI NIH HHS; R01 HL043617-16/HL/NHLBI NIH HHS; R21 AT004277/AT/NCCAM NIH HHS; R21 AT004277-01A2/AT/NCCAM NIH HHS; R21 AT004277-02S1/AT/NCCAM NIH HHS; T32-HL007444/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
8R1V1STN48/Catechin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cardiac origins of the postural orthostatic tachycardia syndrome.
Next Document:  Aspirin for primary prevention of cardiovascular events in people with diabetes.